These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 30819666

  • 21. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A.
    J Clin Oncol; 2013 May 10; 31(14):1767-74. PubMed ID: 23569304
    [Abstract] [Full Text] [Related]

  • 22. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.
    Fedorenko IV, Fang B, Munko AC, Gibney GT, Koomen JM, Smalley KS.
    Proteomics; 2015 Jan 10; 15(2-3):327-39. PubMed ID: 25339196
    [Abstract] [Full Text] [Related]

  • 23. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
    Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, Howle J, Hayward NK, Johansson P, Scolyer RA, Kefford RF, Rizos H.
    Nat Commun; 2014 Dec 02; 5():5694. PubMed ID: 25452114
    [Abstract] [Full Text] [Related]

  • 24. Evaluating melanoma drug response and therapeutic escape with quantitative proteomics.
    Rebecca VW, Wood E, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, Xiang Y, Sarnaik A, Gibney GT, Sondak VK, Koomen JM, Smalley KS.
    Mol Cell Proteomics; 2014 Jul 02; 13(7):1844-54. PubMed ID: 24760959
    [Abstract] [Full Text] [Related]

  • 25. Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
    Garay T, Molnár E, Juhász É, László V, Barbai T, Dobos J, Schelch K, Pirker C, Grusch M, Berger W, Tímár J, Hegedűs B.
    Pathol Oncol Res; 2015 Sep 02; 21(4):957-68. PubMed ID: 25749811
    [Abstract] [Full Text] [Related]

  • 26. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
    Martin CA, Cullinane C, Kirby L, Abuhammad S, Lelliott EJ, Waldeck K, Young RJ, Brajanovski N, Cameron DP, Walker R, Sanij E, Poortinga G, Hannan RD, Pearson RB, Hicks RJ, McArthur GA, Sheppard KE.
    Int J Cancer; 2018 May 15; 142(10):2139-2152. PubMed ID: 29243224
    [Abstract] [Full Text] [Related]

  • 27. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
    Teh JLF, Purwin TJ, Han A, Chua V, Patel P, Baqai U, Liao C, Bechtel N, Sato T, Davies MA, Aguirre-Ghiso J, Aplin AE.
    Mol Cancer Ther; 2020 Aug 15; 19(8):1719-1726. PubMed ID: 32430489
    [Abstract] [Full Text] [Related]

  • 28. Treatment of NRAS-mutant melanoma.
    Johnson DB, Puzanov I.
    Curr Treat Options Oncol; 2015 Apr 15; 16(4):15. PubMed ID: 25796376
    [Abstract] [Full Text] [Related]

  • 29. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
    Lidsky M, Antoun G, Speicher P, Adams B, Turley R, Augustine C, Tyler D, Ali-Osman F.
    J Biol Chem; 2014 Oct 03; 289(40):27714-26. PubMed ID: 25063807
    [Abstract] [Full Text] [Related]

  • 30. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
    Niessner H, Sinnberg T, Kosnopfel C, Smalley KSM, Beck D, Praetorius C, Mai M, Beissert S, Kulms D, Schaller M, Garbe C, Flaherty KT, Westphal D, Wanke I, Meier F.
    Clin Cancer Res; 2017 Oct 15; 23(20):6203-6214. PubMed ID: 28724666
    [Abstract] [Full Text] [Related]

  • 31. Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition.
    Truong A, Yoo JH, Scherzer MT, Sanchez JMS, Dale KJ, Kinsey CG, Richards JR, Shin D, Ghazi PC, Onken MD, Blumer KJ, Odelberg SJ, McMahon M.
    Clin Cancer Res; 2020 Dec 01; 26(23):6374-6386. PubMed ID: 32933997
    [Abstract] [Full Text] [Related]

  • 32. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma.
    Hutchinson KE, Johnson DB, Johnson AS, Sanchez V, Kuba M, Lu P, Chen X, Kelley MC, Wang Q, Zhao Z, Kris M, Berger MF, Sosman JA, Pao W.
    Oncotarget; 2015 Sep 08; 6(26):22348-60. PubMed ID: 26084293
    [Abstract] [Full Text] [Related]

  • 33. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
    Adam C, Fusi L, Weiss N, Goller SG, Meder K, Frings VG, Kneitz H, Goebeler M, Houben R, Schrama D, Schmidt M.
    J Invest Dermatol; 2020 Dec 08; 140(12):2455-2465.e10. PubMed ID: 32376279
    [Abstract] [Full Text] [Related]

  • 34. Loss of keratinocytic RXRα combined with activated CDK4 or oncogenic NRAS generates UVB-induced melanomas via loss of p53 and PTEN in the tumor microenvironment.
    Coleman DJ, Chagani S, Hyter S, Sherman AM, Löhr CV, Liang X, Ganguli-Indra G, Indra AK.
    Mol Cancer Res; 2015 Jan 08; 13(1):186-96. PubMed ID: 25189354
    [Abstract] [Full Text] [Related]

  • 35. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
    Shi H, Kong X, Ribas A, Lo RS.
    Cancer Res; 2011 Aug 01; 71(15):5067-74. PubMed ID: 21803746
    [Abstract] [Full Text] [Related]

  • 36. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.
    Yakovian O, Sajman J, Arafeh R, Neve-Oz Y, Alon M, Samuels Y, Sherman E.
    Cancer Res; 2021 Mar 01; 81(5):1279-1292. PubMed ID: 33355187
    [Abstract] [Full Text] [Related]

  • 37. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.
    Dinter L, Karitzky PC, Schulz A, Wurm AA, Mehnert MC, Sergon M, Tunger A, Lesche M, Wehner R, Müller A, Käubler T, Niessner H, Dahl A, Beissert S, Schmitz M, Meier F, Seliger B, Westphal D.
    Int J Cancer; 2024 Mar 15; 154(6):1057-1072. PubMed ID: 38078628
    [Abstract] [Full Text] [Related]

  • 38. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.
    Rebecca VW, Alicea GM, Paraiso KH, Lawrence H, Gibney GT, Smalley KS.
    Pigment Cell Melanoma Res; 2014 Nov 15; 27(6):1154-8. PubMed ID: 25130256
    [Abstract] [Full Text] [Related]

  • 39. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
    Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, Ortiz-Urda S, Chapman PB, Daud A.
    Pigment Cell Melanoma Res; 2018 Jan 15; 31(1):110-114. PubMed ID: 28921907
    [Abstract] [Full Text] [Related]

  • 40. NRAS mutant melanoma: Towards better therapies.
    Randic T, Kozar I, Margue C, Utikal J, Kreis S.
    Cancer Treat Rev; 2021 Sep 15; 99():102238. PubMed ID: 34098219
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.